Germany Gets Creative with Payer-Pharmaco Contracts
This article was originally published in The Pink Sheet Daily
Executive Summary
Rebate contracts between German insurance funds and generic firms have become widespread since, but the funds are increasingly negotiating deals on innovator drugs as well.
You may also be interested in...
Emerging Markets, Biosimilars May Enhance Suitors' Interest In ratiopharm
More than a year after being put up for sale, German generics firm ratiopharm is now said to have three serious suitors: generics giant Teva, Iceland's Actavis and Pfizer
Emerging Markets, Biosimilars May Enhance Suitors' Interest In ratiopharm
More than a year after being put up for sale, German generics firm ratiopharm is now said to have three serious suitors: generics giant Teva, Iceland's Actavis and Pfizer
Pay-For-Performance Hits France As Part Of Cost-Cutting Measures
Facing a €11 billion ($16 billion) deficit in 2009 in its state-funded health service - which is forecast to reach a whopping €17 billion next year - French ministers announced in late September a series of measures to help curb spending growth